New Releases from NCBI BookshelfRelugolix-Estradiol–Norethindrone Acetate (Myfembree): Indication: Management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women: Reimbursement Recommendation [Internet].​Relugolix-Estradiol–Norethindrone Acetate (Myfembree): Indication: Management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women: Reimbursement Recommendation [Internet].

By /

Canada’s Drug Agency (CDA-AMC) recommends that Myfembree should be reimbursed by public drug plans for the treatment of heavy menstrual bleeding (HMB) from uterine fibroids (UFs) in patients in the premenopausal stage if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top